Department of Medicine

Case Western Reserve University School of Medicine & UH Case Medical Center

Gerald Isenberg, MD, discusses the 10 Worst Foods for Your Stomach with AOL Health

No Comments »
AOL Health
If you think you’re the only one who suffers from belching, stomach bloating and abdominal discomfort on a regular basis, think again: The most current statistics from the Center for Disease Control and Prevention state that the average number of annual visits to physician offices and hospitals regarding digestive system conditions total 42.2 million. And according to the American College of Gastroenterology, more than 95 million Americans suffer from poor digestion.

The common culprits for digestive issues are cooked food, since heat destroys the natural enzymes found in raw foods that aid in digestion, and aging, due to a decline in enzyme production of about 13 percent with each passing decade, said Dr. Steven Lamm, a board-certified internist and faculty member at the NYU Medical Center.

While those who suffer from irritable bowel syndrome, heartburn, acid reflux (also known as gastroesophageal reflux disease) or an ulcer will have various reactions to different foods and drinks, experts agree the following 10 items are likely to irritate one of more of these tummy-related conditions.

Stomach-sensitive food: mint
Why it can affect you: While peppermint has numerous benefits, including aiding in digestive issues, it can also have the reverse effect and increase heartburn symptoms, Dr. Gerald Ashton Isenberg, who works in the gastroenterology department at UH Case Medical Center in Cleveland, Ohio, told AOL Health. “Mint increases the chance of acid reflux because it relaxes the lower esophageal sphincter, a muscle that is located at the end of the esophagus, allowing acid from the stomach to back up into the food pipe,” he explained. Keep in mind this holds true for anything that contains mint, such as peppermint tea and even peppermint gum and breath mints.

Antibiotic may become long-awaited treatment for IBS sufferers

No Comments »

An antibiotic may become the first new treatment in a decade for an extremely common, and sometimes debilitating, digestive disorder. The treatment provided long-lasting relief to patients with diarrhea-predominant irritable bowel syndrome (IBS) in a large clinical trial completed at Cedars Sinai Medical Center in Los Angeles.

The results, published Wednesday in the New England Journal of Medicine, provide solid support for the theory that the symptoms of this difficult-to-treat illness are sometimes caused by excess bacteria in the small intestine.

IBS is a disorder of the lower intestinal tract that causes pain, bloating, nausea, diarrhea and constipation. It affects up to 20 percent of the population, making it one of the most commonly diagnosed disorders, according to the National Institutes of Health.

Dr. Gerard Isenberg, associate chief of gastroenterology at University Hospitals Case Medical Center, has used the therapy on his patients for the past two years as an off-label use. The drug is approved for the treatment of traveler’s diarrhea.

Many have shown dramatic improvement and seen few side effects, he says. “What’s hard about IBS is that it’s usually life-long, and you’re confronted with the question of whether you can repeat treatments of an antibiotic.”

Dr. Gerard Isenberg discusses how antibiotic may become long-awaited treatment for IBS sufferers

No Comments »

cleveland.com
Featured Physician :: Dr. Gerard Isenberg
Division of Gastroenterology and Liver Disease

An antibiotic may become the first new treatment in a decade for an extremely common, and sometimes debilitating, digestive disorder. The treatment provided long-lasting relief to patients with diarrhea-predominant irritable bowel syndrome (IBS) in a large clinical trial completed at Cedars Sinai Medical Center in Los Angeles.

The results, published Wednesday in the New England Journal of Medicine, provide solid support for the theory that the symptoms of this difficult-to-treat illness are sometimes caused by excess bacteria in the small intestine.

CWRUmedicineIBS is a disorder of the lower intestinal tract that causes pain, bloating, nausea, diarrhea and constipation. It affects up to 20 percent of the population, making it one of the most commonly diagnosed disorders, according to the National Institutes of Health.

The treatment, an oral antibiotic called rifaximin, would be the first medication for patients with diarrhea-predominant IBS in more than 10 years if approved by the FDA. The drug is set for review in IBS patients in March.

It may be a boon for a vast number of patients.

Pimentel’s research has shown that between 30 percent and 80 percent of IBS patients, particularly those who suffer primarily from diarrhea, may have bacterial overgrowth and would benefit from rifaximin.

In the current study, a group of more than 1,200 diarrhea-predominant IBS patients gained significant relief from their symptoms — including bloating, pain and diarrhea — from the antibiotic, compared to a placebo.

Rifaximin is different than other antibiotics because it is minimally absorbed and mainly stays in the intestines, reducing side effects, said Pimentel. Symptom relief continued for 10 weeks of follow-up after the initial two-week dose of medication.

IsenbergDr. Gerard Isenberg, associate chief of the Division of Gastroenterology and Liver Disease at University Hospitals Case Medical Center, has used the therapy on his patients for the past two years as an off-label use. The drug is approved for the treatment of traveler’s diarrhea.

Many have shown dramatic improvement and seen few side effects, he says. “What’s hard about IBS is that it’s usually life-long, and you’re confronted with the question of whether you can repeat treatments of an antibiotic.”

Read the full article

Richard Walsh, MD, Chair
discusses 2010 achievements

1 Comment »

Department of Medicine studies vitamin D as way to avert esophageal cancer

No Comments »

For years, researchers have been interested in whether or not there is a link between vitamin D and cancer prevention.

Much of that work has been concentrated in breast, colon and prostate cancers. But researchers at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine have set their sights on the much-less-studied, poor-prognosis esophageal cancer.

A study published in 2006 in the Journal of the National Cancer Institute was one of the first to link low levels of vitamin D with an increased risk of digestive system cancers — including esophageal cancer — in men.

With that study in mind, the researchers here began recruiting patients with Barrett’s esophagus for their study.

Barrett’s is a precancerous condition that about 10 percent of people who have acid reflux develop. With Barrett’s, the lining of the esophagus (the tube from the pharynx that contracts to help move food into the stomach) is damaged and the esophageal sphincter, which helps keep food down, is loosened.

About 1 in 200 of those cases develops into adenocarcinoma esophageal cancer, one of the deadliest cancers to treat. The National Cancer Institute estimates that there will be more than 16,000 new cases diagnosed this year and that 14,500 people will die of it.

“What we’re looking at is a protein called 15-PGDH [15-prostaglandin dehydrogenase],” said gastroenterologist Dr. Linda Cummings, principal investigator of the study. The protein serves as a sort of protective shield that seems to act as a tumor suppressor; the thought is that vitamin D may be linked to an increase in that protein, she said.

Patients in the study, which is being funded by the National Institutes of Health and American College of Gastroenterology, are given 50,000 international units of vitamin D once a week in capsules for up to four months.

Cummings and her colleagues hope to enroll enough patients in the study to collect enough data to design a bigger clinical trial.

“Because esophageal cancer has such a poor prognosis, we’re hoping to prevent patients with Barrett’s from ever getting cancer,” Cummings said.

Barrett’s patients who develop precancerous changes often are subjected to repeated endoscopies, performed under sedation, to monitor those changes.

“In an ideal world, we would give them a [vitamin D] supplement and they wouldn’t have to be subjected to these procedures,” Cummings said.

People get vitamin D from the sun or, if they live in sun-deprived areas such as Northeast Ohio, from supplements and certain foods such as salmon with the skin on and other oily fish.

Vitamin D not only helps develop and maintain healthy bones, but promotes normal cell growth and aids in keeping hormone levels balanced.

The recommended daily dose from food and supplements is 200 IU for people age 50 and under, 400 IU for people ages 51-70, and 600 IU for those over age 70.

Since March 2009, a committee of the Institute of Medicine, which determines those recommendations, has been reviewing those guidelines; a report is expected to be publicly available in November.

Researchers have been conducting studies linking vitamin D deficiency and increased cancer rates for decades. The strongest data out there shows that people with colon cancer have lower vitamin D levels than the rest of the population.

Studies involving prostate and breast cancer, as well as those that seek to show a preventive benefit by taking vitamin D, have been less conclusive.

The newest crop of studies have moved beyond looking at vitamin D levels of people who get certain diseases. More and more, researchers want to find out what happens long term to people who start taking enough vitamin D so their levels are no longer deficient.

At Columbia University, researchers are conducting two different studies looking at whether once-a-week high doses (20,000 or 30,000 IU) of vitamin D for one year will have any effect on preventing breast cancer.

The two-year pilot study of premenopausal women recently completed enrollment. Later this year, a multicenter follow-up study will begin enrolling 200 people.

Researchers at Harvard Medical School and the Brigham and Women’s Hospital in Boston opened enrollment earlier this year for the nationwide VITAL study (VITamin D and OmegA-3 TriaL). The study, which will last at least five years, is investigating whether daily use of vitamin D or fish oil reduces the risk of developing cancer, heart disease and stroke in men age 60 and older and women age 65 and older with no previous history of those diseases.

And a pilot study involving vitamin D and patients with early-stage colorectal cancer will launch in about a month at UH.

Patients will be given two capsules totaling 100,000 IU of vitamin D at the time of their baseline biopsy, and a week before surgery.

The hope, according to UH oncologist Dr. Smitha Krishnamurthi, is that vitamin D will restore 15-PGDH — found in normal cells but discovered in 2004 by researchers at UH and CWRU to be missing in colon cancer cells. If that happens, the 15-PGDH would, in turn, get rid of the substance that triggers the growth of colon cancer.

“If we can demonstrate a higher 15-PGDH, that would have implications for prevention [in other patients],” Krishnamurthi said.

University Hospitals Case Medical Center Remains Among the Elite in U.S. News & World Report Annual Survey

1 Comment »

University Hospitals Case Medical Center (UHCMC) has again ranked among the elite in the latest U.S. News & World Report hospital rankings.  In this year’s survey, UHCMC ranked seven clinical specialties in the top 50 for hospitals and health systems nationwide.

Top among clinical departments at UHCMC, the Department of Medicine again contributed four of the specialties – Gastroenterology (28), Geriatrics (28), Cancer (34), and Pulmonology (42). This contribution by the Department of Medicine figured significantly into UHCMC joining only 152 other hospitals, or the top 3% of the nation’s 5,000 eligible healthcare organizations.

“This consistent level of excellence in compassionate, cost-effective patient care is a testament to the quality and dedication of the full time faculty in the Department of Medicine and to the leadership of our organizations.”

Richard A. Walsh, MD, Chairman, Department of Medicine

CWRUmedicine's Inflammatory Bowel Disease Research Update

No Comments »

Investigators, led by Fabio Cominelli, M.D., Ph.D., formed an integrated team to explore multiple aspects of intestinal inflammation utilizing clinical resources as well as animal models of Crohn’s disease and ulcerative colitis. Some of the topics under investigation include intestinal cytokine regulation, immune-nonimmune cell interactions, extracellular matrix biology, tolerance to indigenous intestinal flora, and state-of-the-art gene expression profiling by DNA microaray technology. In collaboration with the Division of Pediatric Gastroenterology and Nutrition, these investigators have been previously awarded by the National Institutes of Health a large five-year program project grant to study pediatric inflammatory bowel disease, the only such program in the country during that period. Basic research is complemented by a variety of clinical and translational studies. These include investigation of inflammatory bowel disease in minority populations, intestinal permeability in Crohn’s disease families, and an active program of clinical trials with state-of-the-art immunomodulators and biologicals.

Learn more at CWRUmedicine.org

CWRUmedicine 2010 "Best Doctors in America"

No Comments »

Representing the Division of Gastroenterology and Liver Disease, Dr. Fabio Cominelli and Dr Gerard Isenberg were elected to the 2009-2010 Best Doctors in America.

Best Doctors database contains the names and professional affiliations of doctors chosen through a comprehensive peer-review survey that asks: “If you or a loved one needed a doctor in your specialty, to whom would you refer them?” The database represents the top 3 percent to 5 percent of physicians in more than 400 medical subspecialties. A Best Doctors physician goes through regular evaluations by the company in order to maintain his or her status as one of the Best Doctors in America

Read more at CWRUmedicine.org

Videos, Slideshows and Podcasts by Cincopa Wordpress Plugin